MSLN and non-small cell lung carcinoma: They identified a panel of seven glycopeptides, including mesothelin, who performs better than mesothelin alone in detecting MPM vs. non-small cell lung cancer (NSCLC) or pleural benign disease (sensitivity 91% vs. 74%, specificity 78% vs. 74%).